Compare Global X Autonomous & Electric Vehicles (DRIV) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Summit Therapeutics Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.85, while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| DRIV | SMMT | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $26.98 |
52-Week Low | $25.23 | $12.55 |
Market Cap | — | $12.06B |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $35.85, up 0.79% today, with a bullish technical signal from moving averages and oscillators. The stock shows strong momentum, though the 6-day RSI indicates overbought conditions. Recent news highlights global EV sales growth, with DRIV outperforming peers due to its focus on autonomous technology and software, gaining 38% year-to-date according to Seeking Alpha on 2026-05-14.
The outlook remains positive given sector tailwinds, but risks include competitive pressures from Chinese automakers and sensitivity to fuel price fluctuations. Analyst sentiment is bullish, supported by institutional interest in EV and autonomous driving exposure.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
